Cranbury, NJ., April 3, 2018.  Solco Healthcare announced today the launch of Clonidine Hydrochloride Extended-Release Tablets,, a generic version of Kapvay® Tablets by Concordia Pharmaceuticals Inc.  The product is used for the treatment of attention-deficit/hyperactivity disorder (ADHD).

The U.S. Food and Drug Administration (FDA) has granted final approval of its Abbreviated New Drug Application for Clonidine HCl ER Tablets, which was developed and manufactured in collaboration with LP Pharmaceutical (Xiamen) Co., Ltd., and supplied to Solco Healthcare for exclusive distribution in the United States.  Solco is offering Clonidine HCl ER Tablets, 0.1mg, in 60-count bottle to its customers.

“Clonidine ER Tablets is the first product supplied to Solco via our collaboration with LP Pharmaceutical (Xiamen).  We are pleased to add this ADHD prescription treatment to our growing product portfolio and bringing an affordable cost version of this important medication to U.S. patients.” said Hai Wang, President of Solco Healthcare.

According to IQVIA, U.S. brand and generic sales of Clonidine ER tablets were approximately $63.7 million for the 12 months ending in January 2018.